You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36%, and non-GAAP diluted EPS of $20.07, up 70%. It expects an FDA decision in November for semdiceran in generalized myosthenia gravis.
Regeneron Pharmaceuticals, Inc. expanded its Sanofi collaboration in October 2026 to include four additional antibodies, receiving a $1.0 billion up-front payment and up to $7.0 billion in milestones.
Regeneron Pharmaceuticals reported third-quarter 2026 revenues of $5.1 billion, up 36%, and non-GAAP EPS of $20.07, up 70%. Its expanded Sanofi alliance adds $1.0 billion upfront and up to $7.0 billion in future milestones.
Regeneron and Sanofi agreed to co-develop four antibodies, with a $1.0 billion upfront payment and up to $7.0 billion in milestones. Regeneron expects an approximately $22 million pre-tax IPR&D charge and approximately $0.18 diluted-share impact in third quarter 2026.
Regeneron expanded its collaboration with Sanofi to add next-generation type 2 medicines. Regeneron will contribute four long-acting antibodies and receive $1 billion upfront plus up to $7 billion in milestones; the companies will split development costs and global profits 50-50.
Regeneron Pharmaceuticals, Inc. granted Leonard S. Schleifer and George D. Yancopoulos one-time performance share units capped at 2,700,000 and 2,900,000, respectively, over the 10-year period ending December 31, 2035, replacing annual equity awards until 2036.
